ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine kinase inhibitors (TKIs) inhibit the disease-defining BCR::ABL1 fusion kinase, are highly effective for chronic myeloid leukemia (CML), and have revolutionized its treatment.